Respiratory syncytial virus vaccination in pregnancy - Position statement by the European board and college of obstetrics and gynaecology (EBCOG)

The European Board and College of Obstetrics and Gynaecology (EBCOG) expresses its concerns on the morbidity associated with respiratory syncytial virus (RSV) infections in pregnant women and their infants. This position statement reviews the role of maternal vaccination against RSV during the third trimester of pregnancy to reduce the morbidity of RSV in both mother and child. The EBCOG Standing Committee on Standards of Care and Position Statements endorses the recommendation for the administration of 120 μg of a bivalent RSV prefusion F protein-based (RSVpreF) vaccine to pregnant women early in the third trimester. This provides protection against RSV and its attendant comorbidities both to the mother and the infant. Repeat RSV vaccination in subsequent pregnancies is not recommended due to lack of data. regular targeted vaccination of pregnant women.

Published by European journal of obstetrics, gynecology, and reproductive biology, 2025. The guideline itself is at the source linked here.

doi.org/10.1016/j.ejogrb.2025.113978